ONO-AE3-208 |
رقم الكتالوجGC15662
One-Click Copy Product Info
|
ONO-AE3-208 is a prostaglandin receptor (EP) 4-specific antagonist with Ki values of 1.3nM, 30nM, 790nM, and 2400nM for EP4, EP3, PGF, and thromboxane receptors, respectively.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 402473-54-5
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
ONO-AE3-208 is a prostaglandin receptor (EP) 4-specific antagonist with Ki values of 1.3nM, 30nM, 790nM, and 2400nM for EP4, EP3, PGF, and thromboxane receptors, respectively[1]. By targeting EP4, ONO-AE3-208 inhibits blocks the levelsof IL-6 mRNA and IL-6 secretion, and interferes with the activity of the EP4-IL-6 axis pathway to inhibit cell adhesion and migration[2]. ONO-AE3-208 has been widely used in tumor research to reduce tumor metabolism and inhibit angiogenesis[3].
In vitro, ONO-AE3-208 treatment (10µM) for 24 hours significantly inhibited the migration of LNCaP cells, without affecting cell proliferation[4]. 100nM of ONO-AE3-208 pretreatment for 15 minutes attenuated the morphological changes induced by PGE2 in eosinophils and reversed the Ca2+ enhancement[5]. Treatment with 200nM ONO-AE3-208 for 24 hours reduced the activation of the NRLP3 inflammasome and the phosphorylation of NF-κB in the cultured rat peritoneal mesothelial cells (RPMCs)[6].
In vivo, ONO-AE3-208 treatment via oral administration at a dose of 0.5mg/kg/day for 4 weeks reduced angiotensin II infusion-induced abdominal aortic aneurysm formation and inhibited elastic fiber degradation in ApoE−/− mice[7]. Intraventricular injection of ONO-AE3-208 (10nmol) blocked Novokinin-induced anorexigenic activity and promoted food intake in mice that had been fasting for 18 hours within 60 minutes[8]. Oral administration of ONO-AE3-208 at a dose of 10mg/kg/day for 8 weeks alleviated renal injury, reduced proteinuria, and decreased mesangial matrix accumulation in diabetic mice[9].
References:[1] Xu S, Zhang Z, Ogawa O, et al. An EP4 antagonist ONO-AE3-208 suppresses cell invasion, migration, and metastasis of prostate cancer[J]. Cell biochemistry and biophysics, 2014, 70(1): 521-527.
[2] Fukae W, Ishikawa S, Iida Y, et al. EP4 stimulation promotes cell adhesion and migration via IL-6 signaling in oral squamous cell carcinoma[J]. The Journal of Physiological Sciences, 2026: 100057.
[3] Tokumasu M, Nishida M, Kawaguchi T, et al. Blocking EP4 down-regulates tumor metabolism and synergizes with anti-PD-1 therapy to activate natural killer cells in a lung adenocarcinoma model[J]. International Immunology, 2022, 34(6): 293-302.
[4] Xu S, Zhang Z, Ogawa O, et al. An EP4 antagonist ONO-AE3-208 suppresses cell invasion, migration, and metastasis of prostate cancer[J]. Cell biochemistry and biophysics, 2014, 70(1): 521-527.
[5] Luschnig-Schratl P, Sturm E M, Konya V, et al. EP4 receptor stimulation down-regulates human eosinophil function[J]. Cellular and Molecular Life Sciences, 2011, 68(21): 3573-3587.
[6] Luo Q, Liu M, Tan Y, et al. Blockade of prostaglandin E2 receptor 4 ameliorates peritoneal dialysis-associated peritoneal fibrosis[J]. Frontiers in Pharmacology, 2022, 13: 1004619.
[7] Yokoyama U, Ishiwata R, Jin M H, et al. Inhibition of EP4 signaling attenuates aortic aneurysm formation[J]. PloS one, 2012, 7(5): e36724.
[8] Ohinata K, Fujiwata Y, Shingo F, et al. Orally administered novokinin, an angiotensin AT2 receptor agonist, suppresses food intake via prostaglandin E2-dependent mechanism in mice[J]. Peptides, 2009, 30(6): 1105-1108.
[9] Thieme K, Majumder S, Brijmohan A S, et al. EP4 inhibition attenuates the development of diabetic and non-diabetic experimental kidney disease[J]. Scientific Reports, 2017, 7(1): 3442.
| Cell experiment [1]: | |
|
Cell lines |
HSC-3 cells |
|
Preparation Method |
HSC-3 cells were cultured in DMEM medium, supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin, at 37°C in an incubator with 5% CO2. HSC-3 cells were seeded at a density of 1×105 cells per well in 6-well plates and cultured in serum-free medium for 24h. The cells were then stimulated with PGE2 (2μM), ONO-AE1-437 (1μM), or ONO-AE3-208 (1μM). After 1h of stimulation, the culture supernatants were collected and centrifuged at 13000rpm for 10min at 4°C to remove cellular debris. The IL-6 concentration was determined. |
|
Reaction Conditions |
1µM; 1h |
|
Applications |
ONO-AE3-208 treatment reduced IL-6 levels in HSC-3 cells. |
| Animal experiment [2]: | |
|
Animal models |
Male db/db mice |
|
Preparation Method |
Male db/db mice (8 weeks old) were housed in SPF conditions with an automatic 12h/12h light-dark cycle at a constant temperature (21±1°C). Mice were randomly allocated to receive either ONO-AE3-208 (10mg/kg/day in drinking water) or drinking water alone for eight weeks. Blood glucose and urine albumin excretion were determined. |
|
Dosage form |
10mg/kg/day; 8 weeks; p.o. |
|
Applications |
ONO-AE3-208 treatment reduced albuminuria in db/db mice without affecting blood glucose. |
| References: [1] Fukae W, Ishikawa S, Iida Y, et al. EP4 stimulation promotes cell adhesion and migration via IL-6 signaling in oral squamous cell carcinoma[J]. The Journal of Physiological Sciences, 2026: 100057. [2] Thieme K, Majumder S, Brijmohan A S, et al. EP4 inhibition attenuates the development of diabetic and non-diabetic experimental kidney disease[J]. Scientific Reports, 2017, 7(1): 3442. | |
| Cas No. | 402473-54-5 | SDF | |
| Chemical Name | 4-[4-cyano-2-[2-(4-fluoronaphthalen-1-yl)propanoylamino]phenyl]butanoic acid | ||
| Canonical SMILES | CC(C1=CC=C(C2=CC=CC=C21)F)C(=O)NC3=C(C=CC(=C3)C#N)CCCC(=O)O | ||
| Formula | C24H21FN2O3 | M.Wt | 404.43 |
| الذوبان | ≥ 40.4 mg/mL in DMSO with gentle warming, ≥ 8.1 mg/mL in EtOH with ultrasonic and warming | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.4726 mL | 12.3631 mL | 24.7262 mL |
| 5 mM | 494.5 μL | 2.4726 mL | 4.9452 mL |
| 10 mM | 247.3 μL | 1.2363 mL | 2.4726 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)